Moreover, the 36-month beta value for TEVA is 0.61. Analysts have varying opinions on the stock, with 6 analysts rating it as a “buy,” 3 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for TEVA is 1.15B and currently, short sellers hold a 2.48% of that float. On May 19, 2025, TEVA’s average trading volume was 12.74M shares.
TEVA) stock’s latest price update
Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) has seen a rise in its stock price by 0.41 in relation to its previous close of 16.87. However, the company has experienced a 0.06% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-15 that TEL AVIV, Israel, May 15, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Moody’s Investor Services (“Moody’s”) has raised the company’s corporate credit rating to Ba1, outlook stable; from Ba2, outlook positive. Moody’s report cites the Company’s strengths which include significant global scale, ongoing growth in the company’s branded franchises, stabilization of the company’s generics business, focus on debt reduction and resolution of various legal liabilities https://ratings.moodys.com/ratings-news/443085.
TEVA’s Market Performance
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) has experienced a 0.06% rise in stock performance for the past week, with a 26.14% rise in the past month, and a 4.25% rise in the past quarter. The volatility ratio for the week is 4.04%, and the volatility levels for the past 30 days are at 4.02% for TEVA. The simple moving average for the past 20 days is 5.76% for TEVA’s stock, with a -3.41% simple moving average for the past 200 days.
Analysts’ Opinion of TEVA
Many brokerage firms have already submitted their reports for TEVA stocks, with JP Morgan repeating the rating for TEVA by listing it as a “Overweight.” The predicted price for TEVA in the upcoming period, according to JP Morgan is $23 based on the research report published on May 12, 2025 of the current year 2025.
Argus, on the other hand, stated in their research note that they expect to see TEVA reach a price target of $20. The rating they have provided for TEVA stocks is “Buy” according to the report published on July 10th, 2024.
JP Morgan gave a rating of “Neutral” to TEVA, setting the target price at $14 in the report published on March 08th of the previous year.
TEVA Trading at 9.63% from the 50-Day Moving Average
After a stumble in the market that brought TEVA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.70% of loss for the given period.
Volatility was left at 4.02%, however, over the last 30 days, the volatility rate increased by 4.04%, as shares surge +24.10% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.36% upper at present.
During the last 5 trading sessions, TEVA rose by +0.06%, which changed the moving average for the period of 200-days by +3.23% in comparison to the 20-day moving average, which settled at $16.02. In addition, Teva- Pharmaceutical Industries Ltd. ADR saw -23.14% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TEVA starting from Sabag Mark, who sale 337,915 shares at the price of $18.04 back on May 08 ’25. After this action, Sabag Mark now owns 150,996 shares of Teva- Pharmaceutical Industries Ltd. ADR, valued at $6,097,304 using the latest closing price.
Sabag Mark, the Officer of Teva- Pharmaceutical Industries Ltd. ADR, proposed sale 337,915 shares at $18.04 during a trade that took place back on May 08 ’25, which means that Sabag Mark is holding shares at $6,097,324 based on the most recent closing price.
Stock Fundamentals for TEVA
Current profitability levels for the company are sitting at:
- 0.03 for the present operating margin
- 0.49 for the gross margin
The net margin for Teva- Pharmaceutical Industries Ltd. ADR stands at -0.08. The total capital return value is set at 0.02. Equity return is now at value -18.98, with -3.17 for asset returns.
Based on Teva- Pharmaceutical Industries Ltd. ADR (TEVA), the company’s capital structure generated 0.73 points at debt to capital in total, while cash flow to debt ratio is standing at 0.07. The debt to equity ratio resting at 2.71. The interest coverage ratio of the stock is 0.44.
Currently, EBITDA for the company is 716.0 million with net debt to EBITDA at 10.26. When we switch over and look at the enterprise to sales, we see a ratio of 2.09. The receivables turnover for the company is 4.91for trailing twelve months and the total asset turnover is 0.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.03.
Conclusion
To wrap up, the performance of Teva- Pharmaceutical Industries Ltd. ADR (TEVA) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
